Successful treatment using pemigatinib in a myeloid/lymphoid neoplasm with eosinophilia with FGFR1 rearrangement and rare chromosomal abnormalities

Q: What does this research mean for the field?

Pemigatinib is an effective treatment for myeloid/lymphoid neoplasms with eosinophilia harboring FGFR1 rearrangements and rare chromosomal abnormalities. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Masaya Abe; Fumiaki Konishi; Yuki Nakagawa; Kyotaro Ohno; Kumiko Yoshikawa; Nobuhiro Shimizu; Yasuharu Sato; Ichiro Takata; Toru Ueki; Hiroyuki Sugiura

doi:10.1080/10428194.2026.2721772

August 23, 2026Leukemia & lymphoma/Leukemia and lymphoma

Successful treatment using pemigatinib in a myeloid/lymphoid neoplasm with eosinophilia with FGFR1 rearrangement and rare chromosomal abnormalities

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Myeloid/lymphoid neoplasms with eosinophilia (M/LN-eo) and tyrosine kinase gene fusions are rare hematologic malignancies characterized by recurrent rearrangements involving genes such as PDGFRA, P...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Abe et al. (2026) studied this question.

synapsesocial.com/papers/6a8da693e4447a32cadcd4ee https://doi.org/10.1080/10428194.2026.2721772

View at Publisher

Ask AI

Bookmark

Share

Successful treatment using pemigatinib in a myeloid/lymphoid neoplasm with eosinophilia with FGFR1 rearrangement and rare chromosomal abnormalities

Ask about this paper

Abstract

Discussion

Cite This Study

Successful treatment using pemigatinib in a myeloid/lymphoid neoplasm with eosinophilia with FGFR1 rearrangement and rare chromosomal abnormalities

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading